Decision and Details
Receipt of a Warning Letter from the FDA
Because the FDA reviewed the adequacy of the comprehensive response submitted by the company regarding quality management systems and process-related findings identified in Form 483 following an FDA inspection conducted in the second half of 2025
The company does not currently expect this to affect its consolidated results
| Item | Details |
|---|---|
| Matter Covered | Receipt of a Warning Letter from the FDA |
| Decision Date | 7 October 2026 U.S. time (date the Warning Letter was received) |
| Implementation Date | 7 October 2026 (received); response to the FDA planned within 15 business days of receipt |
| Quantity / scale | 6 facilities covered |
| Impact on Business Performance | The company does not currently expect this to affect its consolidated results |
| Reason | Because the FDA reviewed the adequacy of the comprehensive response submitted by the company regarding quality management systems and process-related findings identified in Form 483 following an FDA inspection conducted in the second half of 2025 |
| Governing Rule | Applicable laws and regulations |
| Future plans | The company will submit a response to the FDA within 15 business days of receiving the Warning Letter. If there are any material developments, the company will make appropriate disclosures in accordance with applicable laws and regulations |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because the FDA reviewed the adequacy of the comprehensive response submitted by the company regarding the findings in Form 483 issued following an FDA inspection in the second half of 2025. The company stated that it does not currently expect an impact on consolidated results.